Ontario has seen its second case of a rare blood clotting condition after a man in his 60s got the AstraZeneca vaccine in Hamilton. Hamilton Public Health Services confirmed the case of vaccine-induced immune thrombotic thrombocytopenia (VITT) as a result of a AstraZeneca/COVISHIELD vaccine in a statement on Friday afternoon. Canada has four other official cases of VITT, which is estimated to occur in one out of every 100,000 to 250,000 people vaccinated with the AstraZeneca-Oxford COVID-19 vaccine. WATCH: NACI's Dr. Caroline Quach-Thanh discusses the committee's updated AstraZeneca vaccine recommendations:NACI recommends AstraZeneca vaccine for people aged 30 and older Politics News 1:39 Dr. Shelley Deeks, vice-chair of the National Advisory Committee on Immunization, has announced the committee is recommending the AstraZeneca COVID-19 vaccine be offered to people 30 years and older. This follows the recommendation from NACI to expand the use of the AstraZeneca-Oxford vaccine to all Canadians over the age of 30, but only when the benefits outweigh the risks of the rare blood clots.

Source: CBC News April 23, 2021 23:14 UTC